پادکست های ReachMD

CME credits: 0.50 Valid until: 28-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/targeting-tslp-in-severe-asthma-a-case-based-exploration-for-the-pulmonologist/15831/ The goal of this activity is to use case-based learning to highlight the importance of targeting TSLP in the three types of severe asthma to raise awareness about o…

CME credits: 1.00 Valid until: 30-04-2024 Claim your CME credit at https://reachmd.com/programs/cme/introducing-novel-agents-into-the-armamentarium-for-triple-negative-breast-cancer/15869/ Watch this educational activity to learn about the integration of novel agents into the treatment algorithm for patients with triple-negative breast cancer (TNBC…

CME credits: 1.00 Valid until: 30-04-2024 Claim your CME credit at https://reachmd.com/programs/cme/challenges-in-myelodysplastic-syndromes-mds-risk-stratification-and-integrating-novel-treatment-approaches/15866/ In this eCourse tailored to advanced practice providers, get up to date on optimal care of patients with myelodysplastic syndromes (MDS)…

CME credits: 1.00 Valid until: 30-04-2024 Claim your CME credit at https://reachmd.com/programs/cme/biomarker-testing-in-nsclc-who-what-when/15867/ In this activity, learn about the most recent recommendations for biomarker/molecular testing and personalized treatment plans for patients with non-small-cell lung cancer (NSCLC) based on results from …

CME credits: 1.00 Valid until: 30-04-2024 Claim your CME credit at https://reachmd.com/programs/cme/improving-the-odds-in-metastatic-castrate-sensitive-prostate-cancer/15868/ In this eCourse tailored to advanced practice providers, get up to date on optimal care of metastatic CSPC, including management of treatment-related toxicities and key points…

CME credits: 0.50 Valid until: 19-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/closing-the-gap-personalized-approaches-to-cervical-cancer-screening-and-treatment/15666/ Despite effective screening methods for cervical cancer, many women do not have access or are not screened in a timely manner which results in delayed diagnosis…

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/reconsidering-the-algorithm-treatment-resistant-dme/15860/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do …

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-for-durable-treatment-of-dme/15854/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these…

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/reconsidering-the-algorithm-dme/15859/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and …

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/reconsidering-the-algorithm-namd/15858/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and…

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/a-closer-look-at-real-world-strategies-for-treatment-resistant-dme/15856/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DM…

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/real-world-outcomes-with-durable-treatments-for-retinal-diseases/15855/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)…

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/a-look-at-the-numbers-cost-of-durable-treatments-in-retinal-disease/15857/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (D…

CME credits: 0.25 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/what-you-should-know-about-managing-your-patients-with-both-ckd-and-hyperkalemia/15319/ Patients with heart failure and chronic kidney disease (CKD) are challenging to manage. The best approach is a multidisciplinary one, which will help to optimize …

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-for-durable-treatment-of-namd/15853/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do thes…

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/real-world-treatment-of-retinal-disease/15852/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therap…

CME credits: 0.25 Valid until: 13-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/bridging-the-gap-to-care-what-you-need-to-know-about-attr-cm-amyloidosis/15863/ Once thought to be a rare disease, transthyretin amyloidosis that results in cardiomyopathy (ATTR-CM) remains a challenge to diagnose and treat. In this discussion, Drs. …

CME credits: 1.00 Valid until: 08-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/novel-and-emerging-disease-modifying-therapies-for-mild-cognitive-impairment-due-to-ad-efficacy-and-safety-of-new-dmts-for-mci/16055/ New data and emerging science have significantly advanced our understanding of the pathophysiology of mild cognitive…

CME credits: 1.00 Valid until: 08-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/evolving-treatment-paradigms-for-mild-cognitive-impairment-and-dementia-how-new-dmts-will-fit-into-clinical-practice/16056/ New data and emerging science have significantly advanced our understanding of the pathophysiology of mild cognitive impairmen…

CME credits: 1.00 Valid until: 08-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/evidence-based-discussion-of-the-new-and-emerging-dmt-treatment-strategies-for-mci/16059/ New data and emerging science have significantly advanced our understanding of the pathophysiology of mild cognitive impairment (MCI) and early-onset Alzheimer’…

CME credits: 1.00 Valid until: 08-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/challenges-in-recognizing-and-diagnosing-mci-in-ad-earlier/16053/ New data and emerging science have significantly advanced our understanding of the pathophysiology of mild cognitive impairment (MCI) and early-onset Alzheimer’s disease (AD). The FDA …

CME credits: 1.00 Valid until: 08-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/expert-opinion-on-how-the-new-dmts-fit-into-everyday-clinical-practice/16060/ New data and emerging science have significantly advanced our understanding of the pathophysiology of mild cognitive impairment (MCI) and early-onset Alzheimer’s disease (A…

CME credits: 1.00 Valid until: 08-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/professional-recommendations-of-clinically-validated-tools-used-to-diagnose-mci-in-ad/16058/ New data and emerging science have significantly advanced our understanding of the pathophysiology of mild cognitive impairment (MCI) and early-onset Alzheim…

CME credits: 1.00 Valid until: 08-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/new-data-on-the-pathophysiology-of-mci-and-dementia/16054/ New data and emerging science have significantly advanced our understanding of the pathophysiology of mild cognitive impairment (MCI) and early-onset Alzheimer’s disease (AD). The FDA has rec…

CME credits: 1.00 Valid until: 08-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/disparities-and-inequities-in-the-diagnosis-and-care-of-vulnerable-patient-populations/16057/ New data and emerging science have significantly advanced our understanding of the pathophysiology of mild cognitive impairment (MCI) and early-onset Alzhei…